Sensitive and selective detection of carbamazepine in serum samples by bionic double-antibody sandwich method based on cucurbit[7]uril and molecular imprinted polymers

A novel bionic enzyme-linked immunosorbent assay (BELISA) based on double-antibody sandwich method is firstly designed for the detection of carbamazepine (CBZ) in human serum samples. In this BELISA system, cucurbit[7]uril (CB[7]) is employed as an artificial capture antibody (cAb), and molecularly imprinted polymers (MIPs) is used as an artificial detection antibody (dAb). Nanozymes (PdNPs) as signal generators are integrated with MIPs. This couple of bionic antibodies exhibits not only the excellent physical and chemical stability, but also the superior molecular recognition ability. Based on two bionic antibodies that can selectively recognize different sites of CBZ molecule, a new BELISA method has been constructed for the first time. The proposed BELISA method displays a good linear relationship ranging from 2 to 20 mu g mL(-1). The detection limit is 0.37 mu g mL(-1), which can well meet clinical testing demand. It provides a more stable and economical method for clinical therapeutic drug monitoring (TDM).

Automated summary

A novel bionic enzyme-linked immunosorbent assay (BELISA) based on the double-antibody sandwich method, using cucurbit[7]uril (CB[7]) as a capture antibody and molecularly imprinted polymers (MIPs) as a detection antibody, is developed for the detection of carbamazepine in human serum samples. The proposed BELISA method shows a good linear relationship in the concentration range of 2-20 μg/mL, with a detection limit of 0.37 μg/mL, meeting the clinical testing demand. It provides a more stable and economical method for clinical therapeutic drug monitoring (TDM).